nach phase 3 einstellung absturz von 95%

Bisher nur abwärts ohne Gegenbewegung.

Der Bogen lässt sich nicht endlos spannen.

• MK 32 Mio. $
  
  
  
  
• Cash Ende 2017 ~ 88 Mio. $
  
  
  
• Cash-burn pro Q ~ 13 Mio. $
  
  
  
  
• also nach Q1/18 rund 75 Mio. $
  
  
• -30 Mio. $ Schulden
  
  
• Anzahl Aktien 31 Mio.
  
• Stück
  45 Mio. / 31 Mio. Aktien = Cash pro Aktie 1,45 $
  
  
• Zielkurs: 1,45$
  Potenzial ~+41%
  

• MK 28 Mio. $
  
  
• 
  
     Cash Ende Q1/18 ~ 75 Mio. $
  
     
  
• Cash-burn pro Q ~ 15 Mio. $
  
  
     
  
• also nach Q2/18 rund 60 Mio. $
     
  
• -32 Mio. $ Schulden
     
  
• Anzahl Aktien 31 Mio. Stück
     
  
• 28 Mio. / 31 Mio. Aktien = Cash pro Aktie 0,90 $
     
  
• Zielkurs: 0,90 $
     
  
• Potenzial ~+0 %
  
  
  
  

Sturm im Wasserglas

Fallt nicht darauf rein! Die haben fertig! Alles nur Gezocke!

https://seekingalpha.com/news/...iscloses-study-data-strategic-update

• MK 22 Mio. $
  
• Cash Ende Q3/18 ~ 37 Mio. $
  
• Cash-burn pro Quartal ~ 5 Mio. $
  
• Schulden 7 Mio. $
  
• Anzahl Aktien 31 Mio. Stück
  
• 30 Mio. $ / 31 Mio. Stück = 0,97$ Cash pro Aktie
  
• Zielkurs 0,97$
  
• Potenzial +39%
  

Review of Strategic Alternatives

"Edge continues to be actively engaged in its review of strategic alternatives to maximize stockholder value, a review that was announced in April 2018. At that time, Edge retained Piper Jaffray & Co. to act as its financial advisor to assist with this review process. Potential strategic alternatives that may be explored or evaluated as part of this review include, but are not limited to, an acquisition, merger, business combination or other strategic transaction involving Edge. Edge has reduced the scope of its operations, including the size of its workforce, in order to preserve its cash resources during the strategic alternatives review process"

http://investors.edgetherapeutics.com/...l-newsArticle&ID=2374636

Merger mit PDS Biotech

https://endpts.com/...everse-merging-with-cancer-focused-pds-biotech/

Merger mit PDS Biotechnology abgeschlossen

http://investors.edgetherapeutics.com/...l-newsArticle&ID=2391536